论文部分内容阅读
目的：探索晚期肺腺癌患者化疗疗效和对化疗的耐受性，化疗后生活质量变化和生存期。材料与方法：回顾分析1992－11~1995-04，经病理确诊为肺腺癌。按UICC分期为Ⅲb、Ⅳ期，Kamofsky评分≥60，连续完成2程以上的以铂类药物为主的联合化疗方案治疗患者。结果：化疗有效率3．1％，化疗后Kamofskv评分不变者43．8％，升高40．6％。下降≥10分15．6％，Ⅲb期中位生存期13月，Ⅳ期10月。结论：全身状况较好无化疗禁忌证的晚期肺腺癌患者，给予适当的联合化疗可使部分患者病情改善，生活质量提高。
Objective: To explore the efficacy of chemotherapy and tolerance to chemotherapy in patients with advanced lung adenocarcinoma, quality of life after chemotherapy, and survival time. Materials and Methods: Retrospective analysis was performed from 1992-11 to 1995-04. Lung adenocarcinoma was confirmed by pathology. According to the UICC staging IIIb, IV, Kamofsky score ≥ 60, the platinum-based combination chemotherapy program for patients who completed more than two consecutive courses of treatment. Results: The effective rate of chemotherapy was 3.1%, and the Kamofskv score remained unchanged after chemotherapy was 43.8%, an increase of 40.6%. The decrease was ≥10 points and 15.6%, the median survival time was IIIb, and the IV phase was 10 months. Conclusion: Patients with advanced lung adenocarcinoma with good general condition and no chemotherapy contraindications, appropriate combination of chemotherapy can improve the condition of some patients and improve their quality of life.